Trials / Not Yet Recruiting
Not Yet RecruitingNCT06137300
Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke
Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke：a Multicentre, Prospective, Randomised, Open-label, Blinded-Endpoint Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 986 (estimated)
- Sponsor
- Yi Yang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.
Detailed description
Currently, evidence regarding the safety and efficacy of urinary kallidinogenase treatment in patients with acute ischemic stroke lacks, and few of related studies were large-scale and high-quality. Thus, this study was designed to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Urinary kallidinogenase for injection | Urinary kallidinogenase 0.15PNA once daily for 7 days. |
| OTHER | Guideline-prescribed medical therapy | Guideline-prescribed medical therapy |
Timeline
- Start date
- 2024-03-15
- Primary completion
- 2026-06-30
- Completion
- 2027-12-31
- First posted
- 2023-11-18
- Last updated
- 2024-02-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06137300. Inclusion in this directory is not an endorsement.